Serum miR-16: A Potential Biomarker for Predicting Melanoma Prognosis
Serum miR-16: A Potential Biomarker for Predicting Melanoma Prognosis
复制标题
血清 miR-16：预测黑色素瘤预后的潜在生物标志物
DOI：
10.1016/j.jid.2015.12.041
复制
发表时间：
2016-05-01
影响因子：
6.5
通讯作者：
Li, Chunying
中科院分区：
文献类型：
--
作者：
Guo, Sen;Guo, Weinan;Li, Chunying
黑色素瘤是恶性程度最高的肿瘤之一，其侵袭性是出了名的，进展状况对其预后有很大影响。血清microRNAs是一种小的非编码RNA，在人体血液中具有高度的稳定性和易获得性。它们的表达谱在癌症中经常是失调的；因此，血清microRNAs的水平可以反映黑色素瘤的进展状态，从而预测黑色素瘤的预后。在一项以医院为基础的病例对照研究中，我们发现黑色素瘤患者的血清miR-16水平显著低于非癌症对照组(P<；0.001)。此外，随着肿瘤厚度的增加、溃疡的发生和美国癌症联合委员会的进展，黑色素瘤患者血清miR-16水平显著降低，并且与组织Ki-67的表达高度相关(r=-0.521，P<；0.0001)。Kaplan-Meier分析和Cox比例风险回归分析显示，血清miR-16对预后有预测作用(危险比2.49，95%可信区间1.10-5.63，P=0.028)，独立评估患者的生存结果。最后，在体外和体内验证了miR-16对黑色素瘤生长的抑制作用。综上所述，我们证明血清miR-16是预测黑色素瘤预后的潜在生物标志物。
Melanoma is among the most malignant cancers with notorious aggressiveness, and its prognosis is greatly influenced by progression status. Serum microRNAs are small noncoding RNAs with high stability and easy accessibility in human blood. Their expression profiles are frequently dysregulated in cancers; hence, levels of serum microRNAs may reflect progression status and thus predict melanoma prognosis. In a hospital based case-control study, we found a significant reduction of serum miR-16 level in melanoma patients compared with cancer-free controls (P < 0.001). In addition, serum miR-16 level markedly decreased in melanoma patients with increased tumor thickness, occurrence of ulceration, and advanced American Joint Committee on Cancer stages, and was highly correlated with tissue Ki-67 expression (r = -0.521, P < 0.0001). Kaplan-Meier analysis and Cox proportional hazards regression analysis revealed a prognostic role of serum miR-16 (hazard ratio 2.49, 95% confidence interval 1.10-5.63, P = 0.028), which independently evaluated patients' survival outcome. Finally, the suppressive role of miR-16 in melanoma growth was validated both in vitro and in vivo. In conclusion, we demonstrated that serum miR-16 is a potential biomarker for predicting melanoma prognosis.